Ej. Lewis et al., RO-32-3555, AN ORALLY-ACTIVE COLLAGENASE INHIBITOR, PREVENTS CARTILAGE BREAKDOWN IN-VITRO AND IN-VIVO, British Journal of Pharmacology, 121(3), 1997, pp. 540-546
1 Ro 32-3555 lidinyl)methyl]-4-oxo-4-piperidinobutyrohydroxamic acid)
is a potent, competitive inhibitor of human collagenases 1, 2 and 3 (K
-i values of 3.0, 4.4 and 3.4 nM, respectively). The compound is a sel
ective inhibitor of collagenases over the related human matrix metallo
proteinases stromelysin 1, and gelatinases A and B (K-i values of 527,
154 and 59 nM, respectively). 2 Ro 32-3555 inhibited interleukin-1 al
pha (IL-1 alpha)-induced cartilage collagen degradation in vitro in bo
vine nasal cartilage explants (IC50 = 60 nM). 3 Ro 32-3555 was well ab
sorbed in rats when administered orally. Systemic exposure was dose re
lated, with an oral bioavailability of 26% at a dose of 25 mg kg(-1).
4 Ro 32-3555 prevented granuloma-induced degradation of bovine nasal c
artilage cylinders implanted subcutaneously into rats (ED50 = 10 mg kg
(-1), twice daily, p.o.). 5 Ro 32-3555 dosed once daily for 14 days at
50 mg kg(-1), p.o., inhibited degradation of articular cartilage in a
rat monoarthritis model induced by an intra-articular injection of Pr
opionibacterium acnes. 6 Ro 32-3555 is a potential therapy for the tre
atment of the chronic destruction of articulating cartilage in both rh
eumatoid and osteoarthritis.